{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T14:02:05Z","timestamp":1785074525521,"version":"3.55.0"},"reference-count":150,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2413200\/2023YFC2413204"],"award-info":[{"award-number":["2023YFC2413200\/2023YFC2413204"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bbcan.2026.189656","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:36:55Z","timestamp":1784561815000},"page":"189656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A new chapter in precision medicine: Circulating tumor cells in breast cancer prognosis and treatment"],"prefix":"10.1016","volume":"1881","author":[{"given":"Chentao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaoqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchuan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bbcan.2026.189656_bb0005","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189656_bb0010","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/10815589251366905","article-title":"Liquid biopsy in breast cancer management: from circulating biomarkers to clinical breakthroughs","volume":"74","author":"Ghanim Taki","year":"2026","journal-title":"J. Invest. Med."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189656_bb0015","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/clinchem\/hvab131","article-title":"Programmed cell death ligand 1-expressing circulating tumor cells: a new prognostic biomarker in non-small cell lung Cancer","volume":"67","author":"Sinoquet","year":"2021","journal-title":"Clin. Chem."},{"issue":"15","key":"10.1016\/j.bbcan.2026.189656_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153802","article-title":"A systematic review of circulating tumor cells clinical application in prostate cancer diagnosis","volume":"14","author":"Enikeev","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189656_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22083437","article-title":"Circulating tumour cells as prognostic biomarkers in colorectal cancer: a systematic review","volume":"22","author":"Veyrune","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189656_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics11030513","article-title":"RNA-based CTC analysis provides prognostic information in metastatic breast cancer","volume":"11","author":"Strati","year":"2021","journal-title":"Diagnostics"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189656_bb0035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10549-021-06270-z","article-title":"Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA","volume":"188","author":"Sundaresan","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"issue":"22","key":"10.1016\/j.bbcan.2026.189656_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216198","article-title":"Metastatic ER+ breast cancer: mechanisms of resistance and future therapeutic approaches","volume":"24","author":"Raheem","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189656_bb0045","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/14737159.2019.1631799","article-title":"ESR1 mutations: a new biomarker in breast cancer","volume":"19","author":"Carausu","year":"2019","journal-title":"Expert. Rev. Mol. Diagn."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189656_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112621","article-title":"Detection and characterization of Estrogen receptor \u03b1 expression of circulating tumor cells as a prognostic marker","volume":"14","author":"Ningsi","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189656_bb0055","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41568-022-00536-4","article-title":"Biology, vulnerabilities and clinical applications of circulating tumour cells","volume":"23","author":"Ring","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189656_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40880-018-0346-4","article-title":"The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer","volume":"39","author":"Guan","year":"2019","journal-title":"Cancer Commun. (Lond.)"},{"issue":"6119","key":"10.1016\/j.bbcan.2026.189656_bb0065","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1126\/science.1228522","article-title":"Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition","volume":"339","author":"Yu","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2026.189656_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108709","article-title":"A comprehensive review on the role of nitrogen containing heterocycles in overcoming ABC transporter mediated multidrug resistance in cancer","volume":"163","author":"Naik","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189656_bb0075","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1039\/D0LC01103G","article-title":"Microfluidic studies of hydrostatic pressure-enhanced doxorubicin resistance in human breast cancer cells","volume":"21","author":"Shang","year":"2021","journal-title":"Lab Chip"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189656_bb0080","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1158\/0008-5472.CAN-08-3441","article-title":"Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics","volume":"69","author":"Hennessy","year":"2009","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189656_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21082780","article-title":"Heterogeneity of stemlike circulating tumor cells in invasive breast cancer","volume":"21","author":"Savelieva","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"16","key":"10.1016\/j.bbcan.2026.189656_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14163903","article-title":"Investigating the role of CTCs with stem\/EMT-like features in metastatic breast cancer patients treated with Eribulin mesylate","volume":"14","author":"Papadaki","year":"2022","journal-title":"Cancers"},{"issue":"488","key":"10.1016\/j.bbcan.2026.189656_bb0095","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav0936","article-title":"Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state","volume":"11","author":"Echeverria","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"24","key":"10.1016\/j.bbcan.2026.189656_bb0100","doi-asserted-by":"crossref","first-page":"14811","DOI":"10.1074\/jbc.M115.652628","article-title":"Potentiated DNA damage response in circulating breast tumor cells confers resistance to chemotherapy","volume":"290","author":"Gong","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189656_bb0105","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.celrep.2015.08.050","article-title":"Anti-estrogen resistance in human breast tumors is driven by JAG1-NOTCH4-dependent cancer stem cell activity","volume":"12","author":"Sim\u00f5es","year":"2015","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189656_bb0110","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s10555-023-10124-z","article-title":"How circulating tumor cluster biology contributes to the metastatic cascade: from invasion to dissemination and dormancy","volume":"42","author":"Nasr","year":"2023","journal-title":"Cancer Metastasis Rev."},{"issue":"21","key":"10.1016\/j.bbcan.2026.189656_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215272","article-title":"Circulating tumor cell clusters are cloaked with platelets and correlate with poor prognosis in unresectable pancreatic cancer","volume":"13","author":"Lim","year":"2021","journal-title":"Cancers"},{"issue":"18","key":"10.1016\/j.bbcan.2026.189656_bb0120","doi-asserted-by":"crossref","DOI":"10.1172\/JCI193521","article-title":"Double-positive T cells form heterotypic clusters with circulating tumor cells to foster cancer metastasis","volume":"135","author":"Scholten","year":"2025","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189656_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109547","article-title":"Hypoxia stimulates CTC-platelet cluster formation to promote breast cancer metastasis","volume":"27","author":"Zhou","year":"2024","journal-title":"iScience"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189656_bb0130","article-title":"Tubulin-based microtentacles aid in heterotypic clustering of neutrophil-differentiated HL-60 cells and breast tumor cells","volume":"12","author":"Ju","year":"2025","journal-title":"Adv. Sci. (Weinh)"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189656_bb0135","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1021\/acsnano.3c08946","article-title":"Neutrophil Nanodecoys inhibit tumor metastasis by blocking the interaction between tumor cells and neutrophils","volume":"18","author":"Zeng","year":"2024","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189656_bb0140","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202101761","article-title":"Neutrophil cyto-pharmaceuticals suppressing tumor metastasis via inhibiting hypoxia-inducible factor-1\u03b1 in circulating breast cancer cells","volume":"11","author":"Zhang","year":"2022","journal-title":"Adv. Healthc. Mater."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189656_bb0145","doi-asserted-by":"crossref","first-page":"7649","DOI":"10.1038\/s41467-025-62862-z","article-title":"Computational ranking identifies plexin-B2 in circulating tumor cell clustering with monocytes in breast cancer metastasis","volume":"16","author":"Schuster","year":"2025","journal-title":"Nat. Commun."},{"issue":"20","key":"10.1016\/j.bbcan.2026.189656_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012141","article-title":"Clinical relevancy of circulating tumor cells in breast cancer: epithelial or mesenchymal characteristics, single cells or clusters?","volume":"23","author":"Fridrichova","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.bbcan.2026.189656_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143299","article-title":"In early breast cancer, the ratios of neutrophils, platelets and monocytes to lymphocytes significantly correlate with the presence of subsets of circulating tumor cells but not with disseminated tumor cells","volume":"14","author":"Kasimir-Bauer","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189656_bb0160","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13046-025-03376-w","article-title":"Red blood cell-tumor cell interactions promote tumor cell progression","volume":"44","author":"Pereira-Veiga","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189656_bb0165","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1158\/2159-8290.CD-22-0644","article-title":"Dynamic glycoprotein Hyposialylation promotes chemotherapy evasion and metastatic seeding of quiescent circulating tumor cell clusters in breast cancer","volume":"13","author":"Dashzeveg","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2026.189656_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.116050","article-title":"International expert consensus on the clinical integration of circulating tumor cells in solid tumors","volume":"231","author":"Nicol\u00f2","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189656_bb0175","doi-asserted-by":"crossref","first-page":"26","DOI":"10.33393\/jcb.2023.2629","article-title":"Analytical performance of the FDA-cleared Parsortix(\u00ae) PC1 system","volume":"12","author":"Templeman","year":"2023","journal-title":"J. Circ. Biomark."},{"key":"10.1016\/j.bbcan.2026.189656_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217703","article-title":"Multiplex characterization of circulating tumor cells from ductal carcinoma in situ patients suggests early tumor dissemination","volume":"623","author":"Rupp","year":"2025","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189656_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e29217","article-title":"A real-world comparison of circulating tumor cells in breast cancer from China: novel device, CTC counts and its overall survival","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189656_bb0190","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41551-018-0257-3","article-title":"An intravascular magnetic wire for the high-throughput retrieval of circulating tumour cells in vivo","volume":"2","author":"Vermesh","year":"2018","journal-title":"Nat. Biomed. Eng."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189656_bb0195","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/s41416-023-02179-0","article-title":"Comparative analysis of EpCAM high-expressing and low-expressing circulating tumour cells with regard to their clonal relationship and clinical value","volume":"128","author":"Franken","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"16","key":"10.1016\/j.bbcan.2026.189656_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17162717","article-title":"Comprehensive longitudinal linear mixed modeling of CTCs illuminates the role of Trop2, EpCAM, and CD45 in CTC clustering and metastasis","volume":"17","author":"Merkley","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189656_bb0205","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1039\/D2LC00856D","article-title":"Virtual-freezing fluorescence imaging flow cytometry with 5-aminolevulinic acid stimulation and antibody labeling for detecting all forms of circulating tumor cells","volume":"23","author":"Matsumura","year":"2023","journal-title":"Lab Chip"},{"key":"10.1016\/j.bbcan.2026.189656_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2024.114059","article-title":"An innovative approach to detect circulating tumor cells","volume":"241","author":"Roschenko","year":"2024","journal-title":"Colloids Surf. B: Biointerfaces"},{"issue":"23","key":"10.1016\/j.bbcan.2026.189656_bb0215","doi-asserted-by":"crossref","first-page":"8474","DOI":"10.1039\/D2NR01568D","article-title":"Protein corona-coated immunomagnetic nanoparticles with enhanced isolation of circulating tumor cells","volume":"14","author":"Jiang","year":"2022","journal-title":"Nanoscale"},{"issue":"32","key":"10.1016\/j.bbcan.2026.189656_bb0220","doi-asserted-by":"crossref","first-page":"11885","DOI":"10.1021\/acs.analchem.3c00143","article-title":"Dual stealth functional Immuno-magnetic nanoparticles for high-performance isolation of circulating tumor cells","volume":"95","author":"Jiang","year":"2023","journal-title":"Anal. Chem."},{"key":"10.1016\/j.bbcan.2026.189656_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2024.342381","article-title":"A multilocus-dendritic boronic acid functionalized magnetic nanoparticle for capturing circulating tumor cells in the peripheral blood of mice with metastatic breast cancer","volume":"1297","author":"Chen","year":"2024","journal-title":"Anal. Chim. Acta"},{"issue":"45","key":"10.1016\/j.bbcan.2026.189656_bb0230","doi-asserted-by":"crossref","first-page":"31135","DOI":"10.1021\/acsnano.4c08893","article-title":"Profiling phenotypic heterogeneity of circulating tumor cells through spatially resolved immunocapture on nanoporous micropillar arrays","volume":"18","author":"Lu","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbcan.2026.189656_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2024.116575","article-title":"Combining hybrid cell membrane modified magnetic nanoparticles and inverted microfluidic chip for in situ CTCs capture and inactivation","volume":"263","author":"Sun","year":"2024","journal-title":"Biosens. Bioelectron."},{"issue":"16","key":"10.1016\/j.bbcan.2026.189656_bb0240","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1158\/0008-5472.CAN-17-2459","article-title":"Circulating tumor cells undergoing EMT provide a metric for diagnosis and prognosis of patients with hepatocellular carcinoma","volume":"78","author":"Qi","year":"2018","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189656_bb0245","article-title":"Cluster-based human-in-the-loop strategy for improving machine learning-based circulating tumor cell detection in liquid biopsy","volume":"6","author":"Husseini-W\u00fcsthoff","year":"2025","journal-title":"Patterns (N Y)"},{"issue":"42","key":"10.1016\/j.bbcan.2026.189656_bb0250","doi-asserted-by":"crossref","first-page":"16777","DOI":"10.1021\/acs.analchem.4c03334","article-title":"Deep learning-assisted assessing of single circulating tumor cell viability via cellular morphology","volume":"96","author":"Yang","year":"2024","journal-title":"Anal. Chem."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189656_bb0255","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41588-020-0628-z","article-title":"Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases","volume":"52","author":"Hu","year":"2020","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189656_bb0260","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0163","article-title":"Association of circulating tumor cell status with benefit of radiotherapy and survival in early-stage breast cancer","volume":"4","author":"Goodman","year":"2018","journal-title":"JAMA Oncol."},{"issue":"16","key":"10.1016\/j.bbcan.2026.189656_bb0265","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14163949","article-title":"Does the presence of circulating tumor cells in high-risk early breast cancer patients predict the site of first metastasis-results from the adjuvant SUCCESS a trial","volume":"14","author":"Trapp","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"44","key":"10.1016\/j.bbcan.2026.189656_bb0270","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adz0187","article-title":"Circulating tumor cells as predictive biomarkers in the risk stratification of DCIS: evidence of early dissemination","volume":"11","author":"Nagpal","year":"2025","journal-title":"Sci. Adv."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189656_bb0275","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/PAI.0000000000000186","article-title":"The novel marker GATA3 is significantly more sensitive than traditional markers mammaglobin and GCDFP15 for identifying breast cancer in surgical and cytology specimens of metastatic and matched primary Tumors","volume":"24","author":"Sangoi","year":"2016","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.bbcan.2026.189656_bb0280","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.humpath.2022.04.006","article-title":"TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma","volume":"125","author":"Yoon","year":"2022","journal-title":"Hum. Pathol."},{"issue":"14","key":"10.1016\/j.bbcan.2026.189656_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143341","article-title":"Accurate screening for early-stage breast cancer by detection and profiling of circulating tumor cells","volume":"14","author":"Crook","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2026.189656_bb0290","article-title":"Novel blood based circulating tumour cell biomarker for breast cancer detection","volume":"30","author":"Liu","year":"2019","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189656_bb0295","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/neuonc\/noz012","article-title":"Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications","volume":"21","author":"Boire","year":"2019","journal-title":"Neuro-Oncology"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189656_bb0300","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/clinchem\/hvac127","article-title":"Detection of circulating tumor cells in cerebrospinal fluid of patients with suspected breast cancer leptomeningeal metastases: a prospective study","volume":"68","author":"Darlix","year":"2022","journal-title":"Clin. Chem."},{"issue":"21","key":"10.1016\/j.bbcan.2026.189656_bb0305","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1158\/1078-0432.CCR-08-0030","article-title":"Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial","volume":"14","author":"Pierga","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"20","key":"10.1016\/j.bbcan.2026.189656_bb0310","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1158\/1078-0432.CCR-12-1587","article-title":"Meta-analysis of the prognostic value of circulating tumor cells in breast cancer","volume":"18","author":"Zhang","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189656_bb0315","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.molonc.2016.01.001","article-title":"Circulating tumor cells in breast cancer","volume":"10","author":"Bidard","year":"2016","journal-title":"Mol. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189656_bb0320","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju066","article-title":"Circulating tumor cells predict survival in early average-to-high risk breast cancer patients","volume":"106","author":"Rack","year":"2014","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189656_bb0325","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s12094-015-1372-1","article-title":"Prognostic value of circulating tumor cells in metastatic breast cancer: a systemic review and meta-analysis","volume":"18","author":"Lv","year":"2016","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.bbcan.2026.189656_bb0330","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1272788","article-title":"Factors influencing the diagnostic and prognostic values of circulating tumor cells in breast cancer: a meta-analysis of 8,935 patients","volume":"13","author":"Zhao","year":"2023","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189656_bb0335","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1158\/1078-0432.CCR-24-3108","article-title":"Clinical validity of repeated circulating tumor cell enumeration as an early treatment monitoring tool for metastatic breast cancer in the PREDICT global pooled analysis","volume":"31","author":"Janni","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189656_bb0340","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","article-title":"Liquid biopsy and minimal residual disease - latest advances and implications for cure","volume":"16","author":"Pantel","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189656_bb0345","article-title":"Application status and research progress of targeted therapy drugs for hormone receptor-positive breast cancer","volume":"12","author":"Luo","year":"2025","journal-title":"Front. Med."},{"key":"10.1016\/j.bbcan.2026.189656_bb0350","article-title":"Impact of changing treatment strategy based on circulating tumor cells on postoperative survival of breast cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189656_bb0355","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/jamaoncol.2020.5660","article-title":"Efficacy of circulating tumor cell count-driven vs clinician-driven first-line therapy choice in hormone receptor-positive, ERBB2-negative metastatic breast cancer: the STIC CTC randomized clinical trial","volume":"7","author":"Bidard","year":"2021","journal-title":"JAMA Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189656_bb0360","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-14-1913","article-title":"Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer","volume":"21","author":"Paoletti","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189656_bb0365","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-021-00281-1","article-title":"Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients","volume":"7","author":"Paoletti","year":"2021","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.bbcan.2026.189656_bb0370","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.canlet.2021.12.021","article-title":"AZD5153 reverses palbociclib resistance in ovarian cancer by inhibiting cell cycle-related proteins and the MAPK\/PI3K-AKT pathway","volume":"528","author":"Liu","year":"2022","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189656_bb0375","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","article-title":"Inhibiting CDK4\/6 in breast Cancer with palbociclib, Ribociclib, and Abemaciclib: similarities and differences","volume":"81","author":"Braal","year":"2021","journal-title":"Drugs"},{"issue":"21","key":"10.1016\/j.bbcan.2026.189656_bb0380","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1158\/1078-0432.CCR-25-0327","article-title":"Circulating tumor cell dynamics after CDK4\/6 inhibitor for hormone receptor-positive metastatic breast cancer: a biomarker analysis from the PACE phase II study","volume":"31","author":"Gerratana","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"6_Supplement","key":"10.1016\/j.bbcan.2026.189656_bb0385","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1158\/1538-7445.AM2024-3707","article-title":"Abstract 3707: characterization of estrogen receptor expression on CTCs during CDK4\/6i treatment in HR+\/HER2- metastatic breast cancer: results from the PACE phase II study","volume":"84","author":"Serafini","year":"2024","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189656_bb0390","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-021-01415-w","article-title":"Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial","volume":"23","author":"Galardi","year":"2021","journal-title":"Breast Cancer Res."},{"issue":"302","key":"10.1016\/j.bbcan.2026.189656_bb0395","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aab0021","article-title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","volume":"7","author":"Garcia-Murillas","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189656_bb0400","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jamaoncol.2020.2295","article-title":"Association of Circulating Tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast Cancer: preplanned secondary analysis of the BRE12-158 randomized clinical trial","volume":"6","author":"Radovich","year":"2020","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189656_bb0405","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-25400-1","article-title":"Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer","volume":"13","author":"Stergiopoulou","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189656_bb0410","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41523-024-00642-6","article-title":"Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients","volume":"10","author":"Alba-Bernal","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189656_bb0415","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13058-016-0679-3","article-title":"Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy","volume":"18","author":"Kasimir-Bauer","year":"2016","journal-title":"Breast Cancer Res."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189656_bb0420","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0331203","article-title":"The SURVIVE study (NCT05658172): bringing breast cancer aftercare to the 21stcentury: study protocol of a phase III clinical trial comparing liquid biopsy guided vs. standard of care surveillance for intermediate to high-risk breast cancer survivors","volume":"20","author":"Braun","year":"2025","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189656_bb0425","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1038\/s41416-022-01699-5","article-title":"Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer","volume":"126","author":"Matikas","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189656_bb0430","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211028492","article-title":"Characterization of circulating tumor cells in early breast cancer patients receiving neoadjuvant chemotherapy","volume":"13","author":"Jakabova","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"24","key":"10.1016\/j.bbcan.2026.189656_bb0435","doi-asserted-by":"crossref","first-page":"5178","DOI":"10.1158\/1078-0432.CCR-25-0807","article-title":"Prognostic significance and predictive value of circulating tumor cells in invasive lobular breast carcinoma-an exploratory analysis of the STIC CTC trial","volume":"31","author":"Sandoval","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189656_bb0440","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/clinchem\/hvad144","article-title":"Efficacy of lapatinib in patients with HER2-negative metastatic breast Cancer and HER2-positive circulating tumor cells-the DETECT III clinical trial","volume":"70","author":"Fehm","year":"2024","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bbcan.2026.189656_bb0445","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.breast.2017.01.007","article-title":"Identification of high independent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients","volume":"32","author":"Liu","year":"2017","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189656_bb0450","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mdr263","article-title":"High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients","volume":"23","author":"Pierga","year":"2012","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189656_bb0455","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-63679-4","article-title":"Longitudinal analysis of circulating tumor cell numbers improves tracking metastatic breast cancer progression","volume":"14","author":"Szostakowska-Rodzos","year":"2024","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189656_bb0460","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/jnci\/djaa113","article-title":"Serial analysis of circulating tumor cells in metastatic breast Cancer receiving first-line chemotherapy","volume":"113","author":"Magbanua","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189656_bb0465","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41416-020-01227-3","article-title":"Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial","volume":"124","author":"Cabel","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189656_bb0470","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.5460","article-title":"Evaluating the clinical utility of circulating tumor cells in metastatic breast cancer\u2014is not worse good enough?","volume":"7","author":"Ballinger","year":"2021","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189656_bb0475","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3390\/curroncol30010021","article-title":"Increased circulating epithelial tumor cells (CETC\/CTC) over the course of adjuvant radiotherapy is a predictor of less favorable outcome in patients with early-stage breast cancer","volume":"30","author":"M\u00e4urer","year":"2022","journal-title":"Curr. Oncol."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189656_bb0480","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/14737159.2025.2576021","article-title":"ESR1 ctDNA testing: literature review and comparison of assays for ESR1 mutation detection in advanced hormone receptor-positive breast cancer","volume":"25","author":"Yarunin","year":"2025","journal-title":"Expert. Rev. Mol. Diagn."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189656_bb0485","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/s41416-022-01962-9","article-title":"Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer","volume":"127","author":"Fernandez-Garcia","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189656_bb0490","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/1878-0261.13150","article-title":"Serial monitoring of genomic alterations in circulating tumor cells of ER-positive\/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection","volume":"16","author":"Cani","year":"2022","journal-title":"Mol. Oncol."},{"issue":"20","key":"10.1016\/j.bbcan.2026.189656_bb0495","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1158\/1078-0432.CCR-17-1173","article-title":"Detection of activating Estrogen receptor gene (ESR1) mutations in single circulating tumor cells","volume":"23","author":"Paolillo","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189656_bb0500","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-022-00445-7","article-title":"Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis","volume":"8","author":"Roth\u00e9","year":"2022","journal-title":"npj Breast Cancer"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189656_bb0505","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1158\/0008-5472.CAN-21-2576","article-title":"Hotspot ESR1 mutations are multimodal and contextual modulators of breast cancer metastasis","volume":"82","author":"Li","year":"2022","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189656_bb0510","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/ng.2822","article-title":"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer","volume":"45","author":"Toy","year":"2013","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189656_bb0515","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1158\/0008-5472.CAN-17-2686","article-title":"Comprehensive mutation and copy number profiling in archived circulating breast cancer tumor cells documents heterogeneous resistance mechanisms","volume":"78","author":"Paoletti","year":"2018","journal-title":"Cancer Res."},{"issue":"4785","key":"10.1016\/j.bbcan.2026.189656_bb0520","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189656_bb0525","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2008.19.9844","article-title":"Prognosis of women with metastatic breast Cancer by HER2 status and trastuzumab treatment: an institutional-based review","volume":"28","author":"Dawood","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189656_bb0530","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s11864-023-01137-5","article-title":"Anti-HER2 drugs for the treatment of advanced HER2 positive breast cancer","volume":"24","author":"Stanowicka-Grada","year":"2023","journal-title":"Curr. Treat. Options in Oncol."},{"issue":"20","key":"10.1016\/j.bbcan.2026.189656_bb0535","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"Wolff","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189656_bb0540","doi-asserted-by":"crossref","first-page":"1451471","DOI":"10.3389\/fcell.2025.1451471","article-title":"Advances in research and current challenges in the treatment of advanced HER2-low breast cancer","volume":"13","author":"Qin","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bbcan.2026.189656_bb0545","article-title":"HER2 status of CTCs by peptide-functionalized nanoparticles as the diagnostic biomarker of breast cancer and predicting the efficacy of anti-HER2 treatment","volume":"10","author":"Wang","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189656_bb0550","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25115910","article-title":"Comparing the HER2 status of the primary tumor to that of disseminated tumor cells in early breast cancer","volume":"25","author":"Volmer","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189656_bb0555","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1200\/PO.20.00461","article-title":"Phase II single-arm study to assess trastuzumab and vinorelbine in advanced breast cancer patients with HER2-negative Tumors and HER2-positive circulating tumor cells","volume":"5","author":"Parsons","year":"2021","journal-title":"JCO Precis. Oncol."},{"issue":"13","key":"10.1016\/j.bbcan.2026.189656_bb0560","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14133101","article-title":"Heterogeneity of HER2 expression in circulating tumor cells of patients with breast cancer brain metastases and impact on brain disease control","volume":"14","author":"de Castro","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189656_bb0565","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-015-0624-x","article-title":"Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients","volume":"17","author":"Kallergi","year":"2015","journal-title":"Breast Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189656_bb0570","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1078-0432.CCR-16-3001","article-title":"Breast cancer immunotherapy: facts and hopes","volume":"24","author":"Emens","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189656_bb0575","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189656_bb0580","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/1878-0261.13675","article-title":"Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials","volume":"19","author":"Andresen","year":"2025","journal-title":"Mol. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189656_bb0585","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/clinchem\/hvaa121","article-title":"Clinical correlations of programmed cell death ligand 1 status in liquid and standard biopsies in breast cancer","volume":"66","author":"Jacot","year":"2020","journal-title":"Clin. Chem."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189656_bb0590","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020376","article-title":"Clinical relevance of immune checkpoints on circulating tumor cells in breast cancer","volume":"12","author":"Papadaki","year":"2020","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189656_bb0595","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10549-023-06972-6","article-title":"Efficacy relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy","volume":"200","author":"Zhou","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189656_bb0600","doi-asserted-by":"crossref","first-page":"e2227","DOI":"10.1002\/onco.13981","article-title":"Assessment of PD-L1 expression on circulating tumor cells for predicting clinical outcomes in patients with cancer receiving PD-1\/PD-L1 blockade therapies","volume":"26","author":"Tan","year":"2021","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189656_bb0605","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2326-6066.CIR-14-0133","article-title":"PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer","volume":"3","author":"Wimberly","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189656_bb0610","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1186\/s12885-025-14184-y","article-title":"Establishment of a new method for detection of TROP2-positive circulating tumor cells in breast cancer","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Cancer"},{"issue":"23","key":"10.1016\/j.bbcan.2026.189656_bb0615","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17233885","article-title":"Tracking CTC dynamics: Trop2 and EpCAM in metastatic breast cancer progression","volume":"17","author":"Gonz\u00e1lez","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189656_bb0620","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-61378-8","article-title":"Detection of circulating tumor cells by means of machine learning using Smart-Seq2 sequencing","volume":"14","author":"Pastuszak","year":"2024","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189656_bb0625","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/s41591-024-02934-7","article-title":"Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial","volume":"30","author":"Rod\u00f3n","year":"2024","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189656_bb0630","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1186\/s12885-025-15187-5","article-title":"Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer","volume":"25","author":"Allsopp","year":"2025","journal-title":"BMC Cancer"},{"issue":"16","key":"10.1016\/j.bbcan.2026.189656_bb0635","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14163925","article-title":"Dissecting molecular heterogeneity of circulating tumor cells (CTCs) from metastatic breast cancer patients through copy number aberration (CNA) and single nucleotide variant (SNV) single cell analysis","volume":"14","author":"Rossi","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189656_bb0640","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-024-05616-7","article-title":"Miniaturized protein profiling permits targeted signaling pathway analysis in individual circulating tumor cells to improve personalized treatment","volume":"22","author":"Rivandi","year":"2024","journal-title":"J. Transl. Med."},{"issue":"15","key":"10.1016\/j.bbcan.2026.189656_bb0645","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15153949","article-title":"Cell state and cell type: deconvoluting circulating tumor cell populations in liquid biopsies by multi-omics","volume":"15","author":"Welter","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189656_bb0650","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-018-1663-8","article-title":"Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study","volume":"16","author":"Horimoto","year":"2018","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189656_bb0655","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-024-00623-9","article-title":"Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis","volume":"10","author":"Alkhafaji","year":"2024","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.bbcan.2026.189656_bb0660","first-page":"135684","article-title":"Occult breast lobular carcinoma with numerous circulating tumor cells in peripheral blood","volume":"2015","author":"Ogura","year":"2015","journal-title":"Case Rep. Pathol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189656_bb0665","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1245\/s10434-021-11135-2","article-title":"Circulating tumor cell transcriptomics as biopsy surrogates in metastatic breast cancer","volume":"29","author":"Ring","year":"2022","journal-title":"Ann. Surg. Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189656_bb0670","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1158\/1078-0432.CCR-15-1416","article-title":"Enumeration and molecular characterization of tumor cells in lung cancer patients using a novel in vivo device for capturing circulating tumor cells","volume":"22","author":"Gorges","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"179","key":"10.1016\/j.bbcan.2026.189656_bb0675","doi-asserted-by":"crossref","first-page":"179ra47","DOI":"10.1126\/scitranslmed.3005616","article-title":"Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells","volume":"5","author":"Ozkumur","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbcan.2026.189656_bb0680","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.2147\/IJN.S126823","article-title":"In vivo toxicologic study of larger silica nanoparticles in mice","volume":"12","author":"Chan","year":"2017","journal-title":"Int. J. Nanomedicine"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189656_bb0685","article-title":"Single-cell low-pass whole genome sequencing accurately detects circulating tumor cells for liquid biopsy-based multi-cancer diagnosis","volume":"8","author":"Shen","year":"2024","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.bbcan.2026.189656_bb0690","first-page":"1","article-title":"ESR1 ctDNA testing: literature review and comparison of assays for ESR1 mutation detection in advanced hormone receptor-positive breast cancer","author":"Yarunin","year":"2025","journal-title":"Expert. Rev. Mol. Diagn."},{"issue":"20","key":"10.1016\/j.bbcan.2026.189656_bb0695","doi-asserted-by":"crossref","first-page":"6897","DOI":"10.1158\/1078-0432.CCR-04-0378","article-title":"Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases","volume":"10","author":"Allard","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189656_bb0700","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cyto.a.23571","article-title":"The Parsortix\u2122 cell separation system-a versatile liquid biopsy platform","volume":"93","author":"Miller","year":"2018","journal-title":"Cytometry A"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189656_bb0705","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-024-03149-x","article-title":"Identification of circulating tumor cells captured by the FDA-cleared Parsortix\u00ae PC1 system from the peripheral blood of metastatic breast cancer patients using immunofluorescence and cytopathological evaluations","volume":"43","author":"Ciccioli","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"21","key":"10.1016\/j.bbcan.2026.189656_bb0710","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215238","article-title":"A multi-Center clinical study to harvest and characterize circulating tumor cells from patients with metastatic breast cancer using the Parsortix\u00ae PC1 system","volume":"14","author":"Cohen","year":"2022","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189656_bb0715","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1158\/1078-0432.CCR-09-2042","article-title":"Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial","volume":"16","author":"Riethdorf","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189656_bb0720","article-title":"An exploratory study on the checkout rate of circulating tumor cells and the prediction of efficacy of neoadjuvant therapy and prognosis in patients with HER-2-positive early breast cancer","volume":"12","author":"Zhou","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189656_bb0725","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.11366","article-title":"Evaluation of circulating tumor cells as a prognostic biomarker for early recurrence in stage II\u2013III breast cancer patients using CytoSorter\u00ae system: a retrospective study","volume":"9","author":"Jin","year":"2021","journal-title":"PeerJ"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189656_bb0730","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/ijc.26111","article-title":"Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select\/Detect\u2122 versus Veridex CellSearch\u2122 system","volume":"130","author":"Andreopoulou","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189656_bb0735","doi-asserted-by":"crossref","DOI":"10.6061\/clinics\/2021\/e2971","article-title":"Comparison of hormonal receptor expression and HER2 status between circulating tumor cells and breast cancer metastases","volume":"76","author":"Sanches","year":"2021","journal-title":"Clinics (Sao Paulo)"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189656_bb0740","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.21037\/tcr-19-2662","article-title":"Clinical value and feasibility of ISET in detecting circulating tumor cells in early breast cancer","volume":"9","author":"Zeng","year":"2020","journal-title":"Transl. Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189656_bb0745","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10549-017-4452-9","article-title":"Molecular characterization and heterogeneity of circulating tumor cells in breast cancer","volume":"166","author":"Jakabova","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189656_bb0750","article-title":"Comparative performance of different methods for circulating tumor cell enrichment in metastatic breast cancer patients","volume":"15","author":"Karagiannis","year":"2020","journal-title":"PLoS One"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T13:29:38Z","timestamp":1785072578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26001289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":150,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0304419X26001289"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189656","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new chapter in precision medicine: Circulating tumor cells in breast cancer prognosis and treatment","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189656","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189656"}}